All News

“This vaccine strategy has the potential to be applied to other tumor types,” said Vincent K. Tuohy, PhD, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic Lerner Research Institute, and primary inventor of the vaccine.

In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.

Patients Desiring Immediate Postpartum Sterilization Should Not Be Required to Wait 30 Days.

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.

An update from infectious disease expert, Rana F. Hamdy, MD, on the Omicron variant of COVID-19.

For girls with additional body weight, using Tanner staging to determine pubertal development may require more care.

Here's what's coming to Contemporary OB/GYN this week.

Attention needs to be paid to the psychosocial needs of patients, especially those with poor health-related quality of life, who have little support, or are single mothers.

From 1976 to 2018, data show the prevalence of obesity in the United States increased from 6.2% to 32.7%.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Top tips and HIPAA implications.

Being informed and educated may help patients with breast cancer make a treatment decision and feel less afraid.

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

Here's what's coming up this week on Contemporary OB/GYN.

The trial is the first in the world offering this City of Hope-developed investigational therapy to patients with the hope of one day improving survival for people with triple-negative breast cancer.

"We're moving from an era where it was all based on judgment, and experience, to an era where treatments will be based on firm evidence of the structural failures present in each patient," says Contemporary OB/GYN Advisory Board member John O. L. DeLancey, MD.

Nearly a third of hospital personnel had still not been vaccinated against COVID-19 by mid-September.

It was a busy week for the Contemporary OB/GYN team.

Less than a quarter of physicians could accurately estimate out-of-pocket drug costs.

State legislation that allows adolescents to choose to receive the HPV vaccine without parental interference would elevate immunization rates, according to a new study.

The "Cures 2.0" bill, if signed into law, would expand medical research, aid development of new therapies and expand telehealth.

The AMA continues its fight against COVID-19 disinformation generated by physicians with a new policy.

For the analysis as a whole, “The more localized the copper on an IUD frame and the ability of the frame to conform to the uterine cavity, the more favorable were outcomes at one year,” wrote the authors.

At AAGL’s 50th Global Congress on MIGS, Peter L. Rosenblatt, MD, and Cheryl B. Iglesia, MD, FACOG, debated the use of native tissue repair and transvaginal mesh in pelvic reconstructive surgery.

“Studies like ours may open a new venue of treatment for women with chronic pelvic pain, especially when associated with pelvic floor muscle spasm,” said principal investigator Barbara Karp, MD.

Women exposed to pesticides containing trans-nonachlor were 3.38 times more likely to develop endometriosis (P <0.0001), and for PCB 114 the increased risk was 1.83 (P =0.009).